<DOC>
	<DOC>NCT01885598</DOC>
	<brief_summary>The primary objective of this study is to examine the safety profile of Eliquis in Korean nonvalvular atrial fibrillation patients.</brief_summary>
	<brief_title>Eliquis Regulatory Post Marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Patients â‰¥19 years of age Adult patients who are diagnosed with nonvalvular atrial fibrillation and are initiating Eliquis anticoagulation therapy for risk reduction of stroke and systemic embolism Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study Receiving Eliquis treatment for an indication that is not approved in Korea Contraindicated for the use of Eliquis as described in the Korean label</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>